NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). Shareholders who purchased shares of RCKT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/rocket-pharmaceuticals-inc-loss-submission-form/?id=156721&from=3 CLA ...

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, related to misleading statements about its clinical trials and the safety of its gene therapy product RP-A501 [1][3][4]. Group 1: Lawsuit Details - The class action lawsuit is titled Ho v. Rocket Pharmaceuticals, Inc., and covers purchasers of Rocket Pharmaceuticals securities from February 27, 2025, to May 26, 2025 [1]. - The lawsuit alleges that Rocket Pharmaceuticals provided misleading information regarding the Phase 2 trial of RP-A501 for Danon disease, failing to disclose serious adverse events, including participant deaths [3][4]. - On May 27, 2025, the U.S. FDA placed a clinical hold on the RP-A501 study after a patient died, which was not disclosed to investors prior to the protocol amendment [4]. Group 2: Lead Plaintiff Process - Investors who purchased Rocket Pharmaceuticals securities during the class period can seek to be appointed as lead plaintiff, representing the interests of the class [5]. - The lead plaintiff is typically the investor with the greatest financial interest and must be typical and adequate of the class [5]. Group 3: Company Background - Rocket Pharmaceuticals operates as a late-stage biotechnology company focused on developing gene therapies for rare diseases [2]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized for its significant recoveries in securities fraud cases, having recovered over $2.5 billion for investors in 2024 alone [6].

Core Viewpoint - Rocket Pharmaceuticals is facing a securities class action lawsuit alleging misleading safety disclosures related to its RP-A501 gene therapy program, which has resulted in significant stock price decline following a serious adverse event [1][3]. Company Overview - Rocket Pharmaceuticals, based in Cranbury, New Jersey, specializes in developing gene therapies for rare diseases [2]. Legal Allegations - The lawsuit claims that Rocket Pharmaceuticals did not inform investors about a significant protocol change involving a new immunomodulatory agent before a serious adverse event occurred, leading to a clinical hold by the FDA [3]. - Following the disclosure of a patient death during the trial, Rocket Pharmaceuticals' stock plummeted nearly 37%, dropping from $6.27 on May 23, 2025, to $2.33 on May 27, 2025 [3]. Investor Information - Investors who purchased Rocket Pharmaceuticals securities between February 27, 2025, and May 26, 2025, may be eligible for recovery, with a lead plaintiff application deadline set for August 11, 2025 [4].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after the FDA placed a clinical hold on the study [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for investors affected by alleged securities fraud between February 27, 2025, and May 26, 2025 [1]. - Defendants allegedly provided misleading statements about the safety of RP-A501 while concealing serious adverse events, including participant deaths during the clinical trial [2]. - Following the announcement of the FDA's clinical hold on May 27, 2025, Rocket's stock price plummeted from $6.27 to $2.33 per share, a decline of approximately 37% in one trading day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant time frame have until August 11, 2025, to request appointment as lead plaintiff, although participation does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as a leading securities litigation firm in the United States [4].

Core Viewpoint - Class action lawsuits have been filed on behalf of shareholders of several publicly-traded companies, with specific allegations of misleading statements and undisclosed risks during designated class periods [1][2][3][4][5]. Group 1: Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) - Class period is from February 27, 2025, to May 26, 2025, with a lead plaintiff deadline of August 11, 2025 [2]. - Allegations include that Rocket was aware of serious adverse events (SAEs), including participant deaths, and failed to disclose this risk [2]. - The company amended trial protocols without informing shareholders, leading to misleading positive statements about its business and prospects [2]. Group 2: 3D Systems Corporation (NYSE: DDD) - Class period is from August 13, 2024, to May 12, 2025, with a lead plaintiff deadline of August 12, 2025 [3]. - Allegations state that 3D Systems understated the impact of reduced customer spending and overstated its resilience in tough industry conditions [3]. - The updated milestone criteria negatively impacted the company's Regenerative Medicine Program revenue, resulting in misleading statements about its business outlook [3]. Group 3: Tempus AI, Inc. (NASDAQ: TEM) - Class period is from August 6, 2024, to May 27, 2025, with a lead plaintiff deadline of August 12, 2025 [4]. - Allegations include inflation of contract values and risks associated with the joint venture with SoftBank, which appeared to involve "round-tripping" capital [4]. - Concerns were raised about the business model of Tempus-acquired Ambry, which was based on aggressive billing practices, and reduced financial commitments from AstraZeneca [4]. Group 4: Reddit, Inc. (NYSE: RDDT) - Class period is from October 29, 2024, to May 20, 2025, with a lead plaintiff deadline of August 18, 2025 [5]. - Allegations indicate that changes in Google Search algorithms led to decreased traffic to Reddit, which was not disclosed to investors [5]. - The company misrepresented its user rates and advertising revenue outlook, failing to acknowledge the impact of zero-click searches on its traffic [5].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing allegations of providing misleading information regarding the safety and clinical trial protocol of its RP-A501 treatment, leading to significant stock price decline after the FDA placed a clinical hold on the study due to serious adverse events, including a participant's death [1]. Summary by Sections Allegations - The complaint states that Rocket Pharmaceuticals made overwhelmingly positive statements while concealing material adverse facts about RP-A501's safety and clinical trial protocol [1]. - The company amended the trial protocol to include a new immunomodulatory agent without informing shareholders, which misled investors into purchasing shares at inflated prices [1]. - Following the announcement of the FDA's clinical hold on May 27, 2025, due to a serious adverse event, Rocket's stock price plummeted from $6.27 to $2.33, a decline of approximately 37% in one trading day [1]. Class Action Details - Shareholders who purchased RCKT shares between February 27, 2025, and May 26, 2025, are encouraged to register for the class action lawsuit, with a deadline of August 11, 2025, to seek lead plaintiff status [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [2]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that artificially inflate stock prices [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Rocket Pharmaceuticals securities between February 27, 2025, and May 26, 2025, of the upcoming lead plaintiff deadline on August 11, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Rocket Pharmaceuticals securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by August 11, 2025 [3]. - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Background - The lawsuit alleges that Rocket Pharmaceuticals provided misleading statements regarding the safety and clinical trial protocol of RP-A501, concealing material adverse facts, including the risk of Serious Adverse Events (SAEs) [5]. - The company amended the trial protocol to include a new immunomodulatory agent without informing shareholders, leading to artificially inflated stock prices [5]. - When the true details became public, investors reportedly suffered damages due to the misleading information [5].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after the FDA placed a clinical hold on the study [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for investors affected by alleged securities fraud between February 27, 2025, and May 26, 2025 [1]. - Defendants allegedly provided misleading statements about the safety of RP-A501 while concealing serious adverse events, including participant deaths during the clinical trial [2]. - Following the announcement of the FDA's clinical hold on May 27, 2025, Rocket's stock price plummeted from $6.27 to $2.33 per share, a decline of approximately 37% in one trading day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until August 11, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after the FDA placed a clinical hold on the study [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for investors affected by alleged securities fraud between February 27, 2025, and May 26, 2025 [1]. - Defendants allegedly provided misleading statements about the safety of RP-A501 while concealing serious adverse events, including participant deaths, during the clinical trials [2]. - Following the announcement of the FDA's clinical hold on May 27, 2025, Rocket's stock price plummeted from $6.27 to $2.33 per share, a decline of approximately 37% in one trading day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until August 11, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit due to allegations of providing misleading statements regarding the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after the FDA placed a clinical hold on the study following a Serious Adverse Event [3][4]. Summary by Sections Allegations - The complaint alleges that Rocket Pharmaceuticals made overwhelmingly positive statements to investors while concealing material adverse facts about RP-A501's safety and clinical trial protocol, including the risk of Serious Adverse Events (SAEs) and participant deaths [3]. - The company amended the trial protocol to introduce a new immunomodulatory agent without informing shareholders, leading to artificially inflated stock prices [3]. - Following the announcement of the FDA's clinical hold on May 27, 2025, due to a patient's death, Rocket's stock price plummeted from $6.27 to $2.33, a decline of approximately 37% in one trading day [3]. Class Action Details - The class period for the lawsuit is from February 27, 2025, to May 26, 2025, with a deadline for shareholders to register as lead plaintiffs by August 11, 2025 [4]. - Shareholders who register will receive updates on the case's status through portfolio monitoring software [4]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].